IPOs and Secondaries

IPOs and Secondaries Articles

Sonos entered the markets quietly on Thursday, but shares have quickly climbed since the open in one of the most anticipated IPOs of 2018.
Regional air carrier Mesa Air Group expects to price more than 10 million shares for an initial public offering valued up to more than $184 million.
After a week that saw 11 IPOs enter the public market, the coming week takes a bit of breather with 5 offerings on tap. A top global real estate firm leads the potential entrants.
Tenable appears to be generating a lot more interest with its IPO, and so it has increased its expected price range and share count.
Smart speaker maker Sonos expects to price its almost 14 million shares to result in an initial public offering valued up to more than $303 million.
After firing off nine IPOs last week, the market is expecting 11 more this week seeking a total of $3.4 billion in new funding.
Tilray entered the markets with a bang on Thursday, and it is continuing its run to close out the week. This is one of the first marijuana companies to come public in the United States
Rubius Therapeutics entered the market with a bang in its initial public offering.
Medical cannabis pioneer Tilray expects to price about 9 million shares in an initial public offering valued up to more than $165 million.
Cybersecurity company Tenable intends to sell more than 9 million shares in an initial public offering valued up to about $201 million.
Focus Financial Partners expects to price more than 16 million shares to result in an initial public offering valued up to more than $727 million.
After a slow start to the month, the IPO market returns with a bang in the coming week. There are 10 IPOs on the calendar seeking $1.1 billion in new capital.
Biotechnology company Replimune intends to price more than 6 million shares in an initial public offering valued up to more than $123 million.
Original equipment manufacturer AFG intends to sell more than 18 million shares in an initial public offering valued up to more than $376 million.
Constellation Pharmaceuticals intends to price more than 5 million shares to result in an initial public offering valued up to more than $98 million.